Endocrine Abstracts

BackgroundSodium glucose cotransporter-2 (SGLT-2) inhibitors have proven valuable in the management of type 2 diabetes. These agents are particularly effective in reducing hospitalisations with heart failure and cardiovascular mortality. Adverse effects are primarily centred on urogenital infections and hypovolaemia. Here, we report the case of a patient who developed asymptomatic erythrocytosis while taking empagliflozin.Case repo...